Therapeutic Areas

Precigen Clinical Pipeline and Partnered Programs

As of January 14, 2020

Precigen Preclinical Pipeline

Emerging Therapeutics

Precigen explores emerging therapeutics when there is strategic alignment with the company’s core expertise and potential for patient benefit.

Emerging therapy in otology

Precigen and Novartis are collaborating on CGF166, a recombinant adenovirus 5 (Ad5) vector containing a cDNA encoding the human Atonal transcription factor (Hath1). CGF166 is currently under clinical investigation to evaluate the safety, tolerability, and the potential ability of CGF166 delivered through IL-infusion to improve hearing. Please visit for additional information regarding this clinical study.